EUVIMEDEUVIMED entdecken
Crossref

L26/P-879 cIVF and ICSI result in comparable live birth rates following euploid embryo transfer in non-severe male factor cycles

A. Bayram, I. Elkhatib, S. Siqueira, A. Abdala, V. Ferracuti, H. Didar, N. Hourani, S. Selim, H. Fatemi, D. Nogueira

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Bayram und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does insemination method (cIVF versus ICSI) influence live birth outcomes following euploid embryo transfer in non-severe male factor cycles? Summary answer Live birth rates after single euploid frozen embryo transfer (seFET) were comparable between cIVF and ICSI. What is known already ICSI is widely used in non-severe male factor cycles despite limited evidence of clinical benefit over cIVF. Recent studies indicate that ICSI does not improve live birth rates compared with cIVF. Moreover, the widespread use of ICSI has raised concerns regarding potential long-term implications for offspring. To accurately assess the true clinical efficacy of cIVF, restricting analysis to euploid embryos is particularly relevant. However, downstream reproductive outcomes according to insemination method from PGT-A cycles remain insufficiently explored. Although live birth is a patient-level outcome, sibling-oocyte allocation minimizes biological variability at the embryo origin, which is particularly relevant in this context. Study design, size, duration Observational study conducted at a single IVF centre between June 2017 and October 2024, including 764 seFET cycles derived from cIVF or ICSI in cycles with sibling oocytes inseminated by both methodologies. The median number of sibling oocytes inseminated per cycle was 4 [3–7] by cIVF and 7 [4–10] by ICSI. Participants/materials, setting, methods Euploid embryo transfers from non-severe male factor autologous cycles were included. Baseline characteristics, treatment protocols (hormone replacement therapy, HRT, or natural cycle, NC) and embryo quality were compared. Live birth, defined as delivery of a viable infant, was the primary outcome. Multivariable logistic regression was performed among clinical pregnancies with known outcomes, adjusting for female age, BMI and embryo quality. Main results and the role of chance Median female age (35.0 vs 34.0 years, p = 0.229), BMI (26.5 vs 25.9 kg/m², p = 0.148), previous abortions (0 [0–1] vs 1 [0–2], p = 0.581), HRT use (56.4% vs 54.9%, p = 0.707), good-quality embryo transfer (85.4% vs 87.2%, p = 0.512), were also comparable between transfers derived from cIVF versus ICSI inseminated oocytes. The number of ICSI oocytes (7 [4–10] vs 7 [5–11], p = 0.403) and IVF oocytes (4 [3–7] vs 4 [3–6], p = 0.657) were similar between cases where embryos transferred derived from cIVF and ICSI, respectively.The clinical pregnancy rate per transfer was 65.9% following cIVF (189/287) and 69.8% following ICSI (333/477) (P > 0.05). The live birth rate per transfer was 46.3% for cIVF (133/287) and 47.2% for ICSI (225/477).In multivariable logistic regression analysis, insemination method was not independently associated with live birth (adjusted OR for ICSI vs IVF: 0.76, 95% CI 0.49–1.17). Embryo quality was the strongest predictor of live birth, with good-quality embryos demonstrating nearly two-fold higher odds of live birth compared with poor-quality embryos. BMI showed a borderline inverse association with live birth, while female age was not significantly associated with outcome in the adjusted model. Sensitivity analyses including previous miscarriage did not alter the results. Limitations, reasons for caution The retrospective, observational design and non-random allocation of oocytes between insemination methods limit causal inference. Wider implications of the findings These findings support cIVF as an effective option in PGT-A cycles in non-severe male factor, enabling individualized, evidence-based insemination with balanced laboratory resource use and comparable clinical outcomes. Trial registration number No

Zitieren

APA

Bayram, A., Elkhatib, I., Siqueira, S., Abdala, A., Ferracuti, V., Didar, H., Hourani, N., Selim, S., Fatemi, H., & Nogueira, D. (2026). L26/P-879 cIVF and ICSI result in comparable live birth rates following euploid embryo transfer in non-severe male factor cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1203

Vancouver

Bayram A, Elkhatib I, Siqueira S, Abdala A, Ferracuti V, Didar H, et al. L26/P-879 cIVF and ICSI result in comparable live birth rates following euploid embryo transfer in non-severe male factor cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1203

BibTeX
@article{Bayram2026,
  author = {Bayram, A. and Elkhatib, I. and Siqueira, S. and Abdala, A. and Ferracuti, V. and Didar, H. and Hourani, N. and Selim, S. and Fatemi, H. and Nogueira, D.},
  title = {L26/P-879 cIVF and ICSI result in comparable live birth rates following euploid embryo transfer in non-severe male factor cycles},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1203}
}
Kostenlos starten →